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ARTICLE
Autosomal genetic variation is associated with
DNA methylation in regions variably escaping X-
chromosome inactivation
René Luijk1, Haoyu Wu2, Cavin K Ward-Caviness3, Eilis Hannon4, Elena Carnero-Montoro5,22, Josine L. Min6,7,
Pooja Mandaviya8,9, Martina Müller-Nurasyid 10,11,12, Hailiang Mei2, Silvere M. van der Maarel2,
BIOS Consortium#, Caroline Relton6, Jonathan Mill4, Melanie Waldenberger3,13, Jordana T. Bell5,
Rick Jansen 14, Alexandra Zhernakova15, Lude Franke 15, Peter A.C. ‘t Hoen 2, Dorret I. Boomsma16,
Cornelia M. van Duijn17, Marleen M.J. van Greevenbroek18,19, Jan H. Veldink20, Cisca Wijmenga15,
Joyce van Meurs8, Lucia Daxinger2, P. Eline Slagboom1, Erik W. van Zwet21 & Bastiaan T. Heijmans 1
X-chromosome inactivation (XCI), i.e., the inactivation of one of the female X chromosomes,
restores equal expression of X-chromosomal genes between females and males. However,
~10% of genes show variable degrees of escape from XCI between females, although little is
known about the causes of variable XCI. Using a discovery data-set of 1867 females and 1398
males and a replication sample of 3351 females, we show that genetic variation at three
autosomal loci is associated with female-speciﬁc changes in X-chromosome methylation.
Through cis-eQTL expression analysis, we map these loci to the genes SMCHD1/METTL4,
TRIM6/HBG2, and ZSCAN9. Low-expression alleles of the loci are predominantly associated
with mild hypomethylation of CpG islands near genes known to variably escape XCI, impli-
cating the autosomal genes in variable XCI. Together, these results suggest a genetic basis
for variable escape from XCI and highlight the potential of a population genomics approach to
identify genes involved in XCI.
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To achieve dosage equivalency between male and femalemammals, one of two X-chromosomes is silenced early infemale embryonic development resulting in one inactive
(Xi) and one active (Xa) copy of the X-chromosome1. While the
Xi-linked gene XIST is crucial for the initiation of X-chromosome
inactivation (XCI), autosomal genes appear to be critically
involved in XCI establishment and maintenance2. An abundance
of repressive histone marks3–5 and DNA methylation6,7
throughout XCI on Xi is in line with a prominent role of epi-
genetic regulation in both phases. However, the Xi is not com-
pletely inactivated. With an estimated 15% of X-chromosomal
genes consistently escaping XCI, and an additional 10% escaping
XCI to varying degrees8,9, escape from XCI is fairly common in
humans10–12, much more so than in mice13. Genes escaping XCI
are characterized by distinct epigenetic states14 and are thought to
be associated with adverse outcomes, including mental impair-
ment12–14.
In the mouse, an example of an autosomal gene involved in
XCI is Smchd1. Smchd1 is an epigenetic repressor and plays a
critical role in the DNA methylation maintenance of XCI in
mice15,16. However, in humans, in-depth knowledge on the role
of autosomal genes in XCI maintenance is lacking, despite earlier
in vitro17 efforts. Furthermore, the mechanisms underlying
variable XCI, a common feature of human XCI8,9, are unknown.
Here, we report on the identiﬁcation of four autosomal loci
associated with female-speciﬁc changes in X-chromosome DNA
methylation using a discovery set of 1867 females and 1398
males, and replication of three of these loci in an independent
replication set consisting of 3351 female samples. The repli-
cated loci map to the genes SMCHD1/METTL4, TRIM6/HBG2,
and ZSCAN9 through eQTL analysis. All three preferentially
inﬂuenced the methylation of CpGs located in CpG islands
(CGI) near genes known to variably escape XCI between
individuals, providing evidence for a genetic basis of this
phenomenon.
Results
Identifying female-speciﬁc genetic effects on X-methylation. To
identify genetic variants involved in XCI, we employed a global
test approach18 to evaluate the association of 7,545,443 autosomal
genetic variants with DNA methylation at any of 10,286X-chro-
mosomal CpGs measured in whole blood of 1867 females (Sup-
plementary Data 1) using the Illumina 450k array (see 'Methods').
The analysis was corrected for covariates, including cell counts,
age, and batch effects. We identiﬁed 4504 individual variants
representing 48 independent loci associated with X-chromosomal
methylation in females (Wald P < 5 × 10−8, Fig. 1 and Supple-
mentary Fig. 1), each deﬁned by the most strongly associated
variant (as reﬂected by the lowest P-value), termed the sentinel
variant. Of the 48 sentinel variants corresponding to these 48 loci,
44 were also associated with X-chromosomal methylation in
males (N= 1398, Supplementary Data 1, Supplementary Data 2;
Wald P < 1.1 × 10−6) indicating that the associations were unre-
lated to XCI. The four remaining variants did not show any
indication for an effect in males (Wald P > 0.19) while they did
show strong, widespread, and consistent same-direction effects
across the X-chromosome in females (Supplementary Data 2,
Supplementary Data 3, Supplementary Fig. 2). Formally testing
for a genotype by sex interaction revealed signiﬁcant interaction
effects for three of the four variants. The rs140837774,
rs139916287, and rs1736891 variants with evidence for an
interaction (Pinteraction < 5.9 × 10−4) mapped to the SMCHD1/
METTL4, TRIM6/HBG2, and ZSCAN9 loci, respectively, (see
'Methods'). The remaining variant rs73937272 (Pinteraction= 0.88)
mapped near the ZNF616 gene. Finally, we evaluated whether the
effect of the autosomal loci was inﬂuenced by genetic variation on
X, but this did not change the results (Supplementary Data 4, see
'Methods').
To establish the validity and stability of the analyses, we ﬁrst
investigated whether any of the associations were due to
confounding by cellular heterogeneity. Therefore, we directly
tested for an association between the four identiﬁed sentinel
variants and the observed red and white blood cell counts. This
did not result in any signiﬁcant association (Supplementary
Fig. 3). Furthermore, we determined that none of the four
identiﬁed variants are among the variants known to affect blood
composition19,20. Vice versa, genetic variants known to affect
blood cell counts also did not show an association with X-
chromosomal methylation in our data (Supplementary Fig. 4,
Supplementary Data 5). Re-testing the effects of the four sentinel
variants while adjusting for nearby blood composition-associated
SNPs (<1Mb) did not inﬂuence the results (Supplementary
Data 6, see 'Methods'). Second, we addressed unknown
confounding by including latent factors as covariates in our
models, estimated in the methylation data using software for
estimation and adjustment of unknown confounders in high-
dimensional data21 (see 'Methods'). Re-testing the four sentinel
variants without these latent factors did not change the results
(Supplementary Data 6). We conclude that the effects of the four
variants identiﬁed in the discovery data are stable and not
confounded by cellular heterogeneity or other, unknown, factors.
Finally, we tested the four sentinel variants in an additional
3351 unrelated female samples (see 'Methods' and Supplementary
Data 7), and successfully replicated the rs140837774,
rs139916287, and rs1736891 variants (Bonferroni corrected,
Padj= 0.0096, Padj= 2.4 × 10−4, and Padj= 2.2 × 10−3, respec-
tively). The rs73937272 variant (Padj= 1), which also lacked a
sex-genotype interaction effect in the discovery set, was not
replicated. In further analyses, we focussed on the three replicated
loci.
Exploration of genetic loci affecting X-methylation. The sen-
tinel variant rs140837774 is an AATTG insertion/deletion variant
(MAF= 0.49) on chromosome 18, located in intron 26 of
SMCHD1 (Supplementary Fig. 2), a gene known to be critically
involved in XCI in mice15,22–25. In addition, SMCHD1 mutations
affect the methylation levels of the D4Z4 repeat in humans,
playing an important role in facioscapulohumeral dystrophy 2
(FSHD2)26. To link rs140837774 to a nearby gene we performed a
cis-eQTL analysis using RNA-seq data from the 1867 females in
the discovery set of our study (250 Kb upstream and downstream
of the sentinel variant, Supplementary Data 8). We found that the
deletion was strongly associated with decreased SMCHD1
expression (Fisher’s P= 1.8 × 10−10, regression coefﬁcient=
−0.13) and increased expression of the methyltransferase
METTL4, albeit weaker (Wald P= 4.9 × 10−4, regression coefﬁ-
cient= 0.04). METTL4 is a highly conserved gene27,28, involved
in the mRNA modiﬁcation N6-methyladenosine (reviewed in
ref. 29), which plays an important role in epigenetic regulation in
mammals30.
The SMCHD1/METTL4 variant was associated with altered
methylation levels of 57X-chromosomal CpGs in females (FDR <
0.05, Fig. 2a, Supplementary Data 9). The deletion (the low
SMCHD1 expression allele) was associated with hypomethylation at
56 of those X-chromosomal CpGs (98.2%, binomial P= 8.5 × 10−13
Fig. 2a), consistent with X-hypomethylation in female mice
deﬁcient for SMCHD125. The mean effect size was 1% per rare
allele (ranging from 0.27 to 2.34%, Supplementary Fig. 5), with the
mean methylation values per CpG ranging from 2.6 to 55%
(average methylation at these 56 CpGs is 23.6%).
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Fig. 1 Manhattan plot showing all tested autosomal SNPs for an overall effect on X-chromosomal methylation in females. Signiﬁcant associations are
depicted in blue (Wald P < 5 × 10−8). The sentinel variant per independent locus is indicated with a blue cross. Testing the effects of these 48 sentinel
variants in males, we found 44 replicated in males (Wald P < 1.1 × 10−6, red cross), whereas the other 4 loci were female-speciﬁc, as they clearly lacked an
effect in males (Wald P > 0.19)
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Fig. 2 The SMCHD1/METTL4 locus associates with DNA methylation at X-chromosomal and autosomal regions. a Plot showing the SMCHD1/METTL4 locus
and the effects it has on the X-chromosome. The colors in the SMCHD1/METTL4 locus indicate LD (red: R2≥ 0.8; orange: 0.6≤ R2 < 0.8; green: 0.4≤ R2 <
0.6; light blue: 0.2≤ R2 < 0.4; dark blue: R2 0.6≤ 0.2). The y-axis shows the –log10(P-value) of the association with overall X-chromosomal methylation.
The line colors in the Circos plot indicate the direction of the effect (red: hypomethylation, blue: hypermethylation). The plot of the SMCHD1/METTL4 locus
mostly shows moderate to high LD and covers most of the SMCHD1 gene. The deletion of rs140837774 is associated with both downregulation of SMCHD1
and upregulation of METTL4 (see main text). Its effects on X-chromosomal methylation are abundant and consistent: the deletion of rs140837774 is
associated with hypomethylation at 98.2% of all associated CpGs (56 CpGs, red lines, mean effect size 1% per allele). Hypomethylation of CpGs near two
genes known to escape XCI to varying degrees12 (PIN4 and ALG13, shown in bold) is associated with increased expression of these two genes. b Example of
CpG island (CGI) in the CITED1 gene (ﬁrst row) associated with the SMCHD1/METTL4 locus. The CpGs associated with the SMCHD1/METTL4 locus (ﬁfth
row, indicated by red lines) are overrepresented in regions characterized by both active (blue) and repressive (red) histone marks (second row, red and
blue bars, two-fold enrichment, Fisher’s P= 1.5 × 10−12; 6.9-fold enrichment, Fisher’s P= 1.5 × 10−12), are often located in CpG islands (third row, green
bar, 11.3-fold enrichment, Fisher’s P= 2.5 × 10−14), and regions known to variably escape X-chromosome inactivation10 (fourth row, orange bars, 21.4-fold
enrichment, Fisher’s P= 3.7 × 10−18). The bottom row indicates the strength of the associations in terms of –log10(P-value) (dark red indicates strong
associations)
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Compared to all X-chromosomal CpGs in our data, the
associated X-chromosomal CpGs were strongly overrepresented
in CGI (50 out of 57 CpGs, 11.3-fold enrichment, binomial P=
2.5 × 10−14, Fig. 2b), in line with SMCHD1’s role in X-
chromosomal CGI methylation24. Data on chromatin marks in
blood31 (see 'Methods') revealed a strong overrepresentation of the
associated X-chromosomal CpGs in regions bivalently marked by
the active histone mark H3K4me3 (47 CpGs, 8.2-fold enrichment,
Fisher’s P= 1.5 × 10−12), and the repressive mark H3K27me3 (38
CpGs, 6.9-fold enrichment, Fisher’s P= 1.5 × 10−12), as compared
to all X-chromosomal CpGs in our data. In agreement with this,
we observed a 16.9-fold enrichment for CpGs overlapping
bivalent/poised transcription start sites (TSSs) (35/57 CpGs,
Fisher’s P= 4.3 × 10−23) using predicted chromatin segmenta-
tions31, possibly reﬂecting the mixed signals from both the active
and inactive X chromosomes underlying these chromatin
segmentations. Strikingly, annotation by the degree of escape for
489 TSSs in 27 different tissues, and speciﬁcally whole blood10 (see
'Methods'), revealed a strong overrepresentation of CpGs located
near TSSs variably escaping XCI (22 CpGs, 21.4-fold enrichment,
Fisher’s P= 3.7 × 10−18, Fig. 2b). Only a modest enrichment for
associated CpGs in fully escaping XCI regions (15 CpGs, 4.2-fold
enrichment, Fisher’s P= 4.5 × 10−5) and an underrepresentation
of associated CpGs in inactivated regions (7 CpGs, 28.6-fold
depletion, Fisher’s P= 2.2 × 10−23) was observed.
Further supporting a link with variable XCI, we observed that
X-chromosomal CpGs were associated with differential expres-
sion of the nearby genes (<250 Kb, see 'Methods') ALG13 and
PIN4 (see 'Methods', Supplementary Data 10) both known to
variably escape XCI12. While a strong eQTL effect and a clear
biologically relevant link with XCI mainly implies SMCHD1 in X-
chromosomal hypomethylation (insertion of rs140837774), an
eQTL effect for METTL4, although slightly weaker, leaves open a
possible role for METTL4 in XCI, given its role in the mRNA
modiﬁcation N6-methyladenosine.
Using both female and male samples (N= 3265, Supplemen-
tary Fig. 6) to investigate associations of genetic variation at the
SMCHD1/METTL4 locus with autosomal methylation in trans
(>5Mb), we found that the SMCHD1/METTL4 variant was
associated with 20 CpGs mapping to the HOXD10, HOXC10, and
HOXC11 genes of the HOXD and HOXC clusters located on
chromosomes 2 and 12, as well as to the large protocadherin beta
(PCDHβ) and gamma (PCDHγ) clusters on chromosome 5 (FDR
< 0.05, Supplementary Fig. 7, Supplementary Data 11), all known
SMCHD1 targets25,32.
The second of the three sentinel variants, sentinel SNP
rs139916287 (MAF= 0.07), is located in intron 4 of the HBG2
gene on chromosome 11, in the β-globin locus (rs139916287,
chromosome 11, Supplementary Fig. 2B). The rare allele of the
sentinel variant was associated with decreased expression of both
the HBG2 and TRIM6 genes (T allele; Wald P= 5.3 × 10−7,
regression coefﬁcient=−130.55; Wald P= 9.8 × 10−5, regression
coefﬁcient=−0.05; Supplementary Data 8), based on cis-eQTL
mapping testing genes up to 250 kb upstream, and downstream of
the sentinel variant (Supplementary Data 8). While HBG2
showed higher expression levels and a stronger eQTL effect in
our data, TRIM6 has been shown to bind XIST33, and contributes
to the maintenance of pluripotency in mouse embryonic stem
cells34, making TRIM6 a strong candidate for explaining our
observations. Associating the TRIM6/HBG2 variant with X-
chromosomal methylation, we found 276 associated X-
chromosomal CpG sites (FDR < 0.05, Fig. 3a, Supplementary
Data 9). The rare allele (T allele) was associated with
hypomethylation at 258 of those CpGs (93.5%, binomial P=
6.3 × 10−47), where mean effect size at these 258 CpGs is 1.6% per
T allele, ranging from 0.15% to 4.25% (Supplementary Fig. 5).
ba
AL
G
13
110.922 mb
110.923 mb
110.924 mb
110.925 mb
110.926 mb
110.927 mb
110.928 mb
H
is
to
ne
 m
ar
ks
H3K27me3
H3K4me3
CG
I
Cp
G
XC
I
st
at
us
–Log10(P-value)
0
30
50
60
80
90
10
0
11
0
130
140
150SHROO
M2
ARHGAP4
MO
RF
4L
2
ATP6AP2
TMSB4X
TCEANC
MAGED2
SLITRK4SLITRK2
GPR14
3
CXorf22
CXorf38
GPM6B
IQSEC2
SMC1A
MCT
S1
RENBP
PDHA1
PDZD4
MED14
M
ED12 PO
F1
B
RBBP7
TBL1X
CDKL5
WWC3
NAA10
AL
G1
3
EGFL6
IDH3G
RIBC1
BCOR
YIPF6
PRK
X
HEPH
BE
X2
SSR4
SYP
–
Log 1
0(P-
valu
e) 10
12
8
6
4
2
10
40
70
120
CLCN4
OFD1
20
HG
B2
TR
IM
6
TR
IM
6-
TR
IM
34
TR
IM
34
TRIM
5
TRIM
22
X-chromosome
Fig. 3 The TRIM6/HBG2 locus is associated with DNA methylation at X-chromosomal regions. a Plot showing the TRIM6/HBG2 locus and the widespread
effects it has on the X-chromosome. The colors in the TRIM6/HBG2 locus indicate LD (red: R2≥ 0.8; orange: 0.6≤ R2 < 0.8; green: 0.4≤ R2 < 0.6; light
blue: 0.2≤ R2 < 0.4; dark blue: R2 0.6≤ 0.2). The y-axis shows the –log10(P-value) of the association with overall X-chromosomal methylation. The line
colors in the Circos plot indicate the direction of the effect (red: hypomethylation, blue: hypermethylation). The T allele of its sentinel variant rs139916287
is associated with upregulation of HBG2, downregulation of TRIM6 (both shown in bold), and hypomethylation at 258 of the 276 associated CpGs (93.5%,
red lines, mean effect size 1.6% per allele). X-chromosomal genes whose expression levels were associated with methylation levels of nearby CpGs are
shown in bold. b Example of CpG island (CGI) in the ALG13 gene associated with the TRIM6/HBG2 locus. The enrichments of CpGs in certain genomic
regions are similar to those found for the SMCHD1/METTL4 locus. Most notably, the associated CpGs are also overrepresented in regions known to variably
escape X-chromosome inactivation10 (fourth row, orange bars, 8.8-fold enrichment, Fisher’s P= 2.1 × 10−20)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05714-3
4 NATURE COMMUNICATIONS |  (2018) 9:3738 | DOI: 10.1038/s41467-018-05714-3 | www.nature.com/naturecommunications
Similar to the SMCHD1/METTL4 variant, associated CpGs
were overrepresented in CGIs (199 CpGs, 4.2-fold enrichment,
Fisher’s P= 1.6 × 10−29), and enriched in regions characterized
by H3K27me3 (208 CpGs, 10.5-fold enrichment, Fisher’s P=
3.5 × 10−77) and H3K4me331 (217 CpGs, 6.4-fold enrichment,
Fisher’s P= 5.5 × 10−46, Fig. 3b). The associated CpGs were again
strongly overrepresented in genomic regions variably escaping
XCI in an external set of whole blood samples10 (see 'Methods', 39
CpGs, 8.8-fold enrichment, Fisher’s P= 2.1 × 10−20), to a lesser
extent present in regions consistently escaping XCI (61 CpGs,
6.8-fold enrichment, Fisher’s P= 2.2 × 10−23), and underrepre-
sented in repressed regions (39 CpGs, 15.2-fold depletion, Fisher’s
P= 1.9 × 10−50).
In addition, many genes known to variably escape XCI12,
annotated to CpGs associated with TRIM6/HBG2 genetic variation
(ALG13, ATP6AP2, CXorf38, MED14, SMC1A, TBL1X, Supplemen-
tary Data 10). Similar to SMCHD1/METTL4, these results suggest a
role for the TRIM6/HBG2 locus in variable escape from XCI.
The sentinel SNP of the third identiﬁed locus (rs1736891, MAF
= 0.38) was associated with the expression of several nearby genes
annotated as zinc ﬁngers (Supplementary Data 8), but most strongly
with downregulation of the expression of the nearby transcription
factor35 ZSCAN9 gene located on chromosome 6, based on cis-
eQTL mapping in our own data (Wald P= 2.5 × 10−49, Supple-
mentary Data 8). The sentinel SNP was signiﬁcantly associated with
19X-chromosomal CpGs in females (FDR < 0.05, Supplementary
Fig. 8, Supplementary Data 9), all located in the same CGI: the high-
expression A allele of rs1736891 was associated with mild
hypomethylation of all 19 CpGs (Fisher’s P= 3.6 × 10−5, mean
effect size 1.3% per allele, Supplementary Fig. 5). There was an
overlap of in the CpGs associated with the sentinel variants of the
ZSCAN9 and the SMCHD1/METTL4 locus, although the two loci
are located on different chromosomes (chromosomes 6 and 18,
respectively, Supplementary Fig. 2). These associations were
statistically independent from each other (i.e., additive), as all
identiﬁed loci were identiﬁed using conditional analyses (see
'Methods'). Speciﬁcally, 17 out of 19 CpGs (89.5%) were also
targeted by the SMCHD1/METTL4 locus, and all 19 CpGs show
consistent opposite effects for both loci (Supplementary Fig. 9).
Similar to the SMCHD1/METTL4 locus, the ZSCAN9 locus also
associated with autosomal DNA methylation in trans (>5Mb).
However, none of the autosomal CpGs overlapped between the two
loci (Supplementary Data 11).
Discussion
Here, we identify three autosomal genetic loci with female-
speciﬁc effects on X-chromosomal methylation in humans
(SMCHD1/METTL4, TRIM6/HBG2, and ZSCAN9), all of which
were associated with altered expression of autosomal genes in cis.
Furthermore, all three loci were consistently associated with mild
hypomethylation of CpGs overrepresented in CGI of X-
chromosomal regions known to variably escape XCI in whole
blood10,12. The former ﬁnding extended to 26 other tissues10,
suggesting a cross-tissue genetic basis for variable escape from
XCI. We observed a striking underrepresentation of affected
CpGs in fully inactivated CGIs. This may be due to the tightly
regulated nature of these regions. Methylation of these CpGs may
be impervious to the impact of autosomal genetic variation or
effects may be substantially weaker requiring much larger data
sets to detect them.
While most of the previous work on XCI was done using
mouse models and established a critical role for SMCHD1 in
XCI15,23,25, we here conﬁrm the role of the SMCHD1/METTL4
locus in XCI in humans and highlight its impact on variable
escape from XCI. This phenomenon has not been previously
described in mice, perhaps due to the lack of genetic variability in
the often inbred mice, leading to less (variable) escape from XCI
than occurs in humans8,9. We also observed associations of the
SMCHD1/METTL4 locus with known autosomal SMCHD1
targets25,32, most notably the protocadherin clusters36. Interest-
ingly, similar to the X-chromosome, the expression of the clus-
tered protocadherin genes is stochastic and mono-allelic37,
suggesting a common mechanism.
In addition to the SMCHD1/METTL4 locus, our results indi-
cated a role for the TRIM6/HBG2 locus in XCI. TRIM6 is a strong
candidate to inﬂuence female X-chromosome methylation
because it was reported to bind XIST33 and is involved in MYC
and NANOG regulation34. Similarly, our data suggest a role for
the ZSCAN9 locus in variable escape from XCI, as it affects a
single CGI that is also targeted by the SMCHD1/METTL4 locus.
While this does suggest a role for the two loci in the same
pathway, the effects on the X-chromosome were statistically
independent.
Given the biological consistency of the ﬁndings presented here,
and the replication thereof in an independent set of samples, our
data support a role of autosomal genetic variants in regulating Xi
methylation in particular at variably escaping regions. However,
to deﬁnitely demonstrate causality, unequivocally identify the
responsible genes, and provide precise insight into the exact
underlying mechanisms, in vitro experiments are needed.
Importantly, a population genomics approach, like ours, will
reveal effects on both XCI establishment and maintenance, which
occur during different developmental stages and may involve
different molecular pathways. At this point, the exact role of the
SMCHD1/METTL4, TRIM6/HBG2, and ZSCAN9 loci during
these processes remain to be determined. Therefore, it will be
crucial to design experiments that can discriminate between an
effect during the establishment and maintenance phases.
In conclusion, variable escape from XCI in humans has a
genetic basis and we identiﬁed three autosomal loci, one previous
implicated in XCI in mice and two new loci, that inﬂuence
regions that are susceptible to variable escape from XCI by
controlling X-chromosomal DNA methylation or correlated
epigenetic marks.
Methods
Discovery cohorts. The Biobank-based Integrative Omics Study (BIOS) Con-
sortium comprises six Dutch biobanks: Cohort on Diabetes and Atherosclerosis
Maastricht (CODAM)38, LifeLines-DEEP (LLD)39, Leiden Longevity Study (LLS)
40, Netherlands Twin Registry (NTR)41, Rotterdam Study (RS)42, Prospective ALS
Study Netherlands (PAN)43. Institutional review boards of all cohorts approved
this study (CODAM, Medical Ethical Committee of the Maastricht University; LL,
Ethics committee of the University Medical Centre Groningen; LLS, Ethical
committee of the Leiden University Medical Center; PAN, Institutional review
board of the University Medical Centre Utrecht; NTR, Central Ethics Committee
on Research Involving Human Subjects of the VU University Medical Centre; RS,
Institutional review board (Medical Ethics Committee) of the Erasmus Medical
Center). In addition, informed consent was provided by all participants. The data
that were analyzed in this study came from 3265 unrelated individuals (Supple-
mentary Data 1). Genotype data, DNA methylation data, and gene expression data
were measured in whole blood for all samples. In addition, sex, age, measured cell
counts (lymphocytes, neutrophils, monocytes, eosinophils, basophils, and red
blood cell counts), and information on technical batches were obtained from the
contributing cohorts. The Human Genotyping facility (HugeF, Erasmus MC,
Rotterdam, The Netherlands, http://www.glimdna.org) generated the methylation
and RNA-sequencing data and supplied information on technical batches.
Genotype data were generated within each cohort. Details on the genotyping
and quality control methods have previously been detailed elsewhere (LLD:
Tigchelaar et al.;39 LLS: Deelen et al.44, 2014; NTR: Lin et al.;45 RS: Hofman et al.;42
PAN: Huisman et al.43).
For each cohort, the genotype data were harmonized towards the Genome of
the Netherlands46 (GoNL) using Genotype Harmonizer47 and subsequently
imputed per cohort using Impute248 and the GoNL reference panel (v5)46. We
removed SNPs with an imputation info-score below 0.5, a HWE P-value < 10−4, a
call rate below 95% or a minor allele frequency smaller than 0.01. These imputation
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and ﬁltering steps resulted in 7,545,443 SNPs that passed quality control in each of
the datasets.
A detailed description regarding generation and processing of the gene
expression data can be found elsewhere49. Brieﬂy, total whole blood was processed
using Illumina’s Truseq version 2 library preparation kit. Illumina’s Hiseq2000 was
used for paired-end sequencing. Lastly, CASAVA was used to create read sets per
sample, applying Illumina’s Chastity Filter. Data generation was done by the
Human Genotyping facility (HugeF, ErasmusMC, The Netherlands, see URLs). QC
was performed using FastQC (v0.10.1), cutadapt (v1.1)50, and Sickle (v1.2)51, after
which the sequencing reads were mapped to human genome (HG19) using STAR
(v2.3.0e)52.
All common GoNL SNPs (MAF > 0.01, http://www.nlgenome.nl/?page_id=9)
were masked with N to avoid reference mapping bias. Read pairs used were those
with fewer than nine mismatches, and mapping to fewer than six positions.
Gene expression quantiﬁcation was determined using base counts (for a detailed
description, see ref. 49). The gene deﬁnitions used for quantiﬁcation were based on
Ensembl version 71. For data analysis, we used reads per kilobase per million
mapped reads (RPKM), and only used protein coding genes with sufﬁcient
expression levels (median RPKM > 1), resulting in a set of 10,781 genes. To limit
the inﬂuence of any outliers still present in the data, the data were transformed
using a rank-based inverse normal transformation within each cohort.
The Zymo EZ DNA methylation kit (Zymo Research, Irvine, CA, USA) was
used to bisulﬁte-convert 500 ng of genomic DNA, and 4 μl of bisulﬁte-converted
DNA was measured on the Illumina HumanMethylation450 array using the
manufacturer’s protocol (Illumina, San Diego, CA, USA). Preprocessing and
normalization of the data were done as described earlier53. Removal of
ambiguously mapped probes or probes containing known common genetic
variants54 were removed, followed by quality control (QC) using MethylAid’s55
default settings, investigating methylated and unmethylated signal intensities,
bisulﬁte conversion, hybridization, and detection P-values. Filtering of individual
beta-values was based on detection P-value (P < 0.01), number of beads available
(≤2) or zero values for signal intensity. Normalization was done using Functional
Normalization56 as implemented in the minﬁ R package57, using ﬁve principal
components extracted using the control probes for normalization. All samples or
probes with more than 5% of their values missing were removed, based on the QC
performed using MethylAid. The ﬁnal dataset consisted of 440,825 probes
measured in 3265 samples. Lastly, similar to the RNA-sequencing data, the
methylation data were also transformed using a rank-based inverse normal
transformation within each cohort, to limit the inﬂuence of any remaining outliers
while removing any systematic differences in mean methylation between cohorts.
Replication cohorts. Samples were drawn from the Avon Longitudinal Study of
Parents and Children (ALSPAC) (Fraser et al. 2013; Boyd et al. 2013). Blood from
1022 mother–child pairs (children at three time points and their mothers at two
time points) were selected for analysis as part of Accessible Resource for Integrative
Epigenomic Studies (ARIES, http://www.ariesepigenomics.org.uk/) (Relton et al.
2015). Written informed consent has been obtained for all ALSPAC participants.
Ethical approval for the study was obtained from the ALSPAC Ethics and Law
Committee and the Local Research Ethics Committees. Genotyping and methy-
lation measurements have been previously described58,59.
The University College London case-control sample has been described
elsewhere60,61 but brieﬂy comprises of unrelated ancestrally matched schizophrenia
cases recruited from NHS mental health services and controls from the United
Kingdom. All controls were screened to exclude the presence of an RDC deﬁned
mental disorder, alcohol dependence, or a family history thereof. Informed consent
was obtained from all participating subjects, as well as UK National Health Service
multicentre and local research ethics approval. Details of DNA methylation and
genetic data generation, processing, quality control and normalisation can be found
in the original EWAS manuscript61.
The Aberdeen case-control sample has been described elsewhere61,62 but brieﬂy
contains schizophrenia cases and controls who have self-identiﬁed as born in the
British Isles (95% in Scotland). Controls were selected based on age, sex, and
excluded if they presented with a mental disorder, or one of their ﬁrst degree
relatives, or if they used neuroleptic medication. All subjects gave informed
consent. Different ethical committees (both local and multiregional) approved of
the study. Details of DNA methylation and genetic data generation, processing,
quality control and normalisation can be found in the original EWAS
manuscript61.
The KORA study (Cooperative health research in the Region of Augsburg)
consists of independent population-based samples from the general population
living in the region of Augsburg, Southern Germany. Written informed consent has
been given by each participant and the study was approved by the local ethical
committee. The dataset comprised individuals from the KORA F4 survey (all with
genotyping and methylation data available) conducted during 2006–2008.
The TwinsUK cohort recruits monozygotic and dizygotic twins since its
establishment in 199263, includes over 13,000 twin participants, and is a good
representation of the general population in the UK and represents this population
with respect to several phenotypes, including disease64. As such, it has been used in
several epidemiological studies.
The Rotterdam Study (RS) is a prospective, population-based cohort study,
investigating chronic diseases in the elderly65. The study consists of several cohorts
(RS-I, RS-II, RS-III), totalling 14,926 subjects from the Ommoord district in
Rotterdam, The Netherlands. All participants gave informed consent. This study
was approved by the Erasmus University Medical Center medical ethics committee.
Discovering female-speciﬁc genetic effects on X-methylation. To identify
autosomal genetic variants inﬂuencing DNA methylation anywhere on the X-
chromosome we applied a two-step approach18 using 1867 female samples from
the replication cohorts for which both genotype data and methylation data were
available. We ﬁrst ﬁtted linear models to test for an association between each
autosomal SNP yj and each of 10,286X-chromosomal CpGs xi individually, cor-
recting for known covariates M (cell counts, cohort, age, technical batches—e.g.,
sample plate and array position) and unknown confounding by including latent
factors U, estimated using cate21, where the eigenvalue difference method imple-
mented in cate suggested an optimal number of three latent factors:
yj ¼ βijxi þ γM þ δU ð1Þ
For each autosomal genetic variant i, this approach yields 10,286 P-values pij.
Next, we combined all 10,286 P-values corresponding to one genetic variant i into
one overall P-value Pi using the Simes procedure66, yielding 7,545,443 P-values Pi,
one for each autosomal genetic variant tested. This overall P-value per SNP
indicates if an autosomal SNP inﬂuences DNA methylation anywhere on the X-
chromosome, reducing this analysis to a GWAS for X-chromosomal DNA
methylation. SNPs with an overall P-value < 5 × 10−8 were deemed signiﬁcantly
associated with X-chromosomal DNA methylation.
To identify independent effects among the identiﬁed variants, we performed
iterative conditional analyses. We re-ran the entire above procedure, correcting for
the strongest associated sentinel variant, as determined by the lowest overall P-
value.
yj ¼ βijxi þ γM þ δU þ βtop SNPxsentinel ð2Þ
Having identiﬁed a new top SNP at the same genome-wide signiﬁcance level of
P < 5 × 10−8, we again re-did our analysis, now correcting for two top SNPs. We
repeated this process until no new independent effects were identiﬁed, which was
after 47 such iterations, thus yielding 48 sentinel variants, corresponding to 48
different loci.
Next, to establish the female-speciﬁcity of the identiﬁed loci on X-chromosomal
methylation, we aimed to validate the 48 identiﬁed loci in 1398 males from the
discovery cohorts for which the same genotype and methylation data were
available. Any locus also having an effect in males would then mean that particular
locus was not female speciﬁc. To do this, we tested the sentinel variant per locus
found in females in the exact same way as we did in females, but also testing all
SNPs within 1 Mb correlated to the sentinel variant (R2 ≥ 0.8 in males). A locus
with any SNP having an overall P-value Pi ≤ 0.05 in males was not considered to be
female-speciﬁc, yielding four loci with four corresponding sentinel variants.
Replicating female-speciﬁc genetic effects on X-methylation. To replicate the
four identiﬁed sentinel variants, we used an independent sample of 3351 females
from ﬁve different replication cohorts (see section Description of replication
cohorts), all having genotype and 450 k methylation data available. Similar to the
discovery phase, each of four sentinel variants xi was associated with all X-
chromosomal CpGs yj in each replication cohort k:
yjk ¼ βijkxik ð3Þ
each yielding a test-statistic tijk. We then combined the test-statistics corresponding
to each genetic variant i and CpG j between each cohort j using Stouffer’s weighted
Z-method (discussed in ref. 67), resulting in one overall Z-score Zij for each variant-
CpG pair i,j:
Zij ¼
P
k
wktijkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
k
w2k
p ð4Þ
where wk indicates the sample size for replication cohort k. Converting each overall
Z-score Zij to a P-value pij, we again used the Simes’ procedure66 to calculate one
overall P-value Pi per genetic variant i, representing the statistical evidence for an
association with any X-chromosomal CpG in the replication cohorts.
Local (cis) expression QTL mapping. In order to map the identiﬁed sentinel
variants associated with female-speciﬁc X-chromosomal methylation to nearby
genes, we employed cis-eQTL mapping in the discovery cohorts, where we asso-
ciated the genotypes of a genetic variant i with the expression levels of genes j in cis
(<250 Kb). Similar to the trans-meQTL mapping for chromosome X, we corrected
for known covariates M (i.e., cell counts, cohort, age, technical batches), and
unknown confounding U using cate, using an optimal number of latent factors to
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include, as suggested by cate:
yj ¼ βijxi þ γM þ δU ð5Þ
Next, we performed the Bonferroni correction to the corresponding P-values pij
to identify genes associated with the genetic variant.
Associating X-methylation with nearby gene expression. To identify genes
associated with DNA methylation of nearby CpGs (<250 Kb), we used a similar
model as for trans-meQTL and cis-eQTL mapping. We associated methylation
levels of CpGs xi with the observed expression values of a gene yj using a linear
model, correcting for covariates M (i.e., cell counts, cohort, age, technical batches):
yj ¼ βijxi þ γM ð6Þ
The Bonferroni correction was used to determine signiﬁcant CpG-gene pairs.
Identifying genetic effects on autosomal DNA methylation. To identify long-
range effects (>5Mb) of a genetic variant on DNA methylation at autosomal CpGs,
we performed trans-meQTL mapping using all 3265 samples for which both
genotype data and methylation data were available, as we expected these effects to
be present in both women and men (Supplementary Fig. 6). For any genetic variant
i and CpG j, we ﬁtted a linear model correcting for known covariates M (cell
counts, cohort, age, technical batches), and unknown confounding U using cate:
yj ¼ βijxi þ γM þ δU ð7Þ
The FDR was controlled within each set of corresponding P-values pij, to obtain
a list of associated CpGs for a genetic variant i.
Testing epistatic effects. To test if the identiﬁed autosomal loci have any epistatic
effects on X-chromosomal DNA methylation, we corrected the analysis for X-
chromosomal cis-meQTLs. We ﬁrst mapped cis-meQTLs (<250 Kb) on the X-
chromosome by testing all nearby genetic variants for an effect on any of the X-
chromosomal CpGs associated with one of the three autosomal loci. For any
genetic variant i and CpG j, we ﬁtted a linear model correcting for known cov-
ariates M (cell counts, cohort, age, technical batches):
yj ¼ βXij xi þ γM ð8Þ
We corrected for multiple testing using the Bonferroni procedure, selecting
CpGs harboring cis-meQTLs. Next, we re-tested the effects of the autosomal loci on
the X-chromosomal CpGs, but this time correcting for the strongest cis-SNP.
yj ¼ βXij þ βautoij xi þ γM ð9Þ
Annotations and enrichment tests. CpGs were annotation using UCSC Genome
Browser68, histone marks and chromatin states data from the Blueprint Epigenome
data69, transcription factor binding site (TFBS) data from the Encode Project70,
and data on regions escaping X-inactivation10. All annotations were done based on
the location of the CpG site using HG19/GRCh37.
The CGI track from the UCSC Genome Browser was used to map CpGs to
CGIs. Shores were deﬁned as the ﬂanking 2 kb regions. All other regions were
deﬁned as non-CGI.
We obtained Epigenomics Roadmap ChIP-seq data on histone marks measured
in blood-related cell types (the GM12878 lymphoblastoid cell line, the K562
leukemia cell line, and monocytes). We selected ﬁve different histone marks for
which data measured in both men and women were available (H3K4me3,
H3K4me1, H3K9me3, H3K27me3, H3K27ac). A CpG was said to overlap with any
histone mark if it did so in any the of the data sets.
We obtained Epigenomics Roadmap data on the 16 predicted core chromatin
states data in blood-related cell types (the GM12878 lymphoblastoid cell line, the
K562 leukemia cell line, and monocytes). A CpG was said to overlap with any
chromatin state if it did so in any of the available data sets for that histone mark.
Likewise, we obtained transcription factor binding data from the Encode Project,
using blood-related cell types only (GM08714, GM10847, GM12878, GM12892,
GM18505, GM18526, GM18951, GM19099, GM19193).
The degree of escape from X-inactivation for 632 TSSs has previously been
established in 27 different tissues10. Within each tissue, each TSS was said to fully
escape XCI, variably escape XCI, or be subject to XCI. We mapped each X-
chromosomal CpG to the nearest such TSS, annotating each CpG with the
accompanying scores for each of the 27 tissues. CpGs not in the vicinity of any such
TSS (>10 kb, 4698 CpGs) were left unannotated.
In order to determine the enrichment of CpGs for any of the described genomic
contexts, we used Fisher’s exact test, where the used all X-chromosome CpGs as the
background set.
Code availability. R code is available from https://git.lumc.nl/r.luijk/
ChromosomeX. This repository describes the main analyses done.
Data availability
Raw data were submitted to the European Genome-phenome Archive (EGA) under
accession EGAS00001001077.
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